Pathological examination of image-guided tumor biopsy has been the gold standard for cancer diagnosis for decades. Nowadays, in this era of precision oncology and personalized medicine, tumor biopsy assessment has greatly expanded its roles in studying disease progression, drug efficacy, and developing biomarkers in clinical studies via performing a wide range of assays such as molecular profiling, flow cytometry, immunohistochemistry, etc.1-3 insufficiency or low quality of biopsy could lead to failure of downstream assays and hamper any dependent treatment decisions, therefore be a barrier to precision medicine.4